NEXTURN BIO INC
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company 2022-02-22 20:52
Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc. 2021-05-30 22:00
Nexturn Bio Inc. decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA 2021-05-07 07:00
The world's first-in-class miRNA therapeutics to cure diabetes by pancreatic beta cell regeneration 2021-05-07 07:00
1